The objective of this study is to measure the impact of MenAfriVac® vaccine in the African meningitis belt using high-quality surveillance data.

AMP will collaborate with the Centers for Disease Control and Prevention (CDC) and WHO Regional Office for Africa (AFRO) to determine the project strategy, choose surveillance sites, develop common protocols, monitor sites closely to check the quality of work, and obtain data regularly.

Currently, the study covers Togo, Burkina Faso, Niger, and Mali. Two additional countries will be chosen for the period 2015-2018.